drugset / Trial / NCT02131636

Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

NCT02131636

Phase 3 Completed 440 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety and efficacy of AGN-199201 once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.

Timeline

Start
2014-05
Primary completion
2014-11
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxymetazoline Other / unclassified Topical

Indications